Current treatment strategies with lenalidomide in multiple myeloma and future perspectives.
暂无分享,去创建一个
[1] R. Mina,et al. Management of older adults with multiple myeloma. , 2013, Blood reviews.
[2] I. Flinn,et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. , 2012, Blood.
[3] M. Beksac,et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. , 2012, The New England journal of medicine.
[4] B. Pégourié,et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.
[5] K. Owzar,et al. Lenalidomide after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.
[6] M. Beksac,et al. IMWG consensus on maintenance therapy in multiple myeloma. , 2012, Blood.
[7] G. Morgan,et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. , 2012, Blood.
[8] C. Chen,et al. A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma , 2012, Leukemia.
[9] M. Boccadoro,et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. , 2012, Blood.
[10] G. Roodman,et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. , 2011, Blood.
[11] I. Yakoub-Agha,et al. Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agents , 2012, Leukemia.
[12] J. Pinilla-Ibarz,et al. Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia. , 2012, Cancer control : journal of the Moffitt Cancer Center.
[13] P. Fenaux,et al. Immunomodulating drugs in myelodysplastic syndromes. , 2011, Hematology. American Society of Hematology. Education Program.
[14] P. Sonneveld,et al. Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients , 2011 .
[15] B. Pégourié,et al. Bortezomib, Lenalidomide, and Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Frontline Multiple Myeloma Patients: Updated Results of the IFM 2008 Phase II VRD Intensive Program , 2011 .
[16] K. Griffith,et al. Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM) , 2011 .
[17] A. Oriol,et al. Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. , 2011, Blood.
[18] G. Morgan,et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). , 2011, Blood.
[19] A. Palumbo,et al. Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy , 2011, Leukemia.
[20] P. Fayers,et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. , 2011, Blood.
[21] M. Kaminski,et al. Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. , 2011, Blood.
[22] J. Vose,et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] S. Jagannath,et al. Phase I trial of elotuzumab, lenalidomide, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] U. Mellqvist,et al. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement , 2011, Leukemia.
[25] S. Lonial,et al. Treatment Options for Relapsed and Refractory Multiple Myeloma , 2011, Clinical Cancer Research.
[26] J. Trapani,et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. , 2011, Blood.
[27] J. Crowley,et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). , 2010, Blood.
[28] F. Prósper,et al. Smoldering Multiple Myeloma (SMM) at High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) as Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment , 2010 .
[29] Michael L. Wang,et al. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma , 2010, Haematologica.
[30] J. Leonard,et al. Clarithromycin (Biaxin)‐lenalidomide‐low‐dose dexamethasone (BiRd) versus lenalidomide‐low‐dose dexamethasone (Rd) for newly diagnosed myeloma , 2010, American journal of hematology.
[31] H. Goldschmidt,et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function , 2010, Cancer.
[32] D. Esseltine,et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] M. Kersten,et al. Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program. , 2010, Clinical lymphoma, myeloma & leukemia.
[34] J. Zeldis,et al. Lenalidomide in multiple myeloma: current role and future directions , 2010, Expert opinion on pharmacotherapy.
[35] M. Boccadoro,et al. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] E. Terpos,et al. Treatment with deferasirox (Exjade®) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study , 2010, British journal of haematology.
[37] R. Fonseca,et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. , 2010, The Lancet. Oncology.
[38] D. Esseltine,et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] M. Dimopoulos,et al. Neutropenia Is a Predictable and Early Event in Affected Patients with Relapsed/Refractory Multiple Myeloma Treated with Lenalidomide in Combination with Dexamethasone. , 2009 .
[40] B. Barlogie,et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review , 2009, Leukemia.
[41] K. Anderson,et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. , 2009, Blood.
[42] S. Lonial. Risky business in myeloma. , 2009, Blood.
[43] M. Dimopoulos,et al. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma , 2009, European journal of haematology.
[44] D. Esseltine,et al. Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] S. Lonial,et al. Panobinostat plus lenalidomide and dexamethasone phase I trial in multiple myeloma (MM). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] H. Einsele,et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). , 2009, Blood.
[47] J. Reynolds,et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] H. Brenner,et al. Expected long-term survival of patients diagnosed with multiple myeloma in 2006–2010 , 2008, Haematologica.
[49] M. Dimopoulos,et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma , 2009, Leukemia.
[50] Michael L. Wang,et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. , 2008, Blood.
[51] D. Siegel,et al. A Phase I Study of Vorinostat in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma , 2008 .
[52] I. Lossos,et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] Bin Jiang,et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. , 2008, The New England journal of medicine.
[54] N. Munshi,et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. , 2008, Blood.
[55] J. Leonard,et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[56] X. Armoiry,et al. Lenalidomide in the treatment of multiple myeloma: a review , 2008, Journal of clinical pharmacy and therapeutics.
[57] S. Jagannath,et al. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients , 2008, Leukemia.
[58] D. Dingli,et al. Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.
[59] H. Brenner,et al. Recent major improvement in long-term survival of younger patients with multiple myeloma. , 2008, Blood.
[60] B. Barlogie,et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma , 2008, Leukemia.
[61] J. Leonard,et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. , 2008, Blood.
[62] H. Goldschmidt,et al. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone , 2008, Annals of Hematology.
[63] O. Laskin,et al. Pharmacokinetics of Lenalidomide in Subjects With Various Degrees of Renal Impairment and in Subjects on Hemodialysis , 2007, Journal of clinical pharmacology.
[64] Michael Wang,et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. , 2007, The New England journal of medicine.
[65] Alessandro Corso,et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. , 2007, The New England journal of medicine.
[66] N. Callander,et al. Phase II Trial of Bevacizumab Combined with Low Dose Dexamethasone and Lenalidomide (BEV/REV/DEX) for Relapsed or Refractory Myeloma (MM). , 2007 .
[67] P. L. Bergsagel,et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. , 2007, Mayo Clinic proceedings.
[68] R. Fonseca,et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma , 2007, Leukemia.
[69] G. Morgan,et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients , 2007, British journal of haematology.
[70] K. Anderson,et al. A Multicenter Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (Dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM). , 2006 .
[71] M. Dimopoulos,et al. Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials. , 2006 .
[72] Diane Warren,et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. , 2006, Blood.
[73] Robert A Kyle,et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. , 2005, Blood.
[74] A. Dalgleish,et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. , 2005, Microvascular research.
[75] R. Kyle,et al. Drug therapy: Multiple myeloma , 2004 .
[76] Angus G. Dalgleish,et al. The evolution of thalidomide and its IMiD derivatives as anticancer agents , 2004, Nature Reviews Cancer.
[77] Richard LeBlanc,et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. , 2002, Blood.
[78] N. Munshi,et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. , 2002, Blood.
[79] B. Barlogie,et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. , 2001, Blood.
[80] G Muller,et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. , 2000, Blood.
[81] L. Corral,et al. Immunomodulation by thalidomide and thalidomide analogues , 1999, Annals of the rheumatic diseases.
[82] Gilla Kaplan,et al. Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production , 1999 .
[83] Mike Clarke,et al. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[84] H. Wilson,et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. , 1969, JAMA.